Informations:
Erreur:
ID
21236
Description
Evaluation of a New Agent for Treatment of Advanced Stage Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00313248
Lien
https://clinicaltrials.gov/show/NCT00313248
Mots-clés
Versions (1)
- 16/04/2017 16/04/2017 -
Téléchargé le
16 avril 2017
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Eligibility Breast Neoplasm NCT00313248
Eligibility Breast Neoplasm NCT00313248
- StudyEvent: Eligibility
Similar models
Eligibility Breast Neoplasm NCT00313248
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
metastatic breast cancer
Item
metastatic breast cancer (meaning the cancer has spread beyond its original location)
boolean
C0278488 (UMLS CUI [1])
breast cancer measurable lesion
Item
at least one measurable lesion by ct or mri
boolean
C0006142 (UMLS CUI [1,1])
C1513041 (UMLS CUI [1,2])
C0011923 (UMLS CUI [1,3])
C1513041 (UMLS CUI [1,2])
C0011923 (UMLS CUI [1,3])
progression after breast cancer therapy
Item
progression of disease following previous therapy for breast cancer
boolean
C0006142 (UMLS CUI [1,1])
C0087111 (UMLS CUI [1,2])
C0242656 (UMLS CUI [1,3])
C0087111 (UMLS CUI [1,2])
C0242656 (UMLS CUI [1,3])
anthracyclines or taxanes therapy
Item
have received previous treatment with anthracyclines (e.g. doxorubicin[adriamycin or doxil] or epirubicin [ellence]), taxanes (paclitaxel [taxol or abraxane] or docetaxel [taxotere]) for your breast cancer
boolean
C0282564 (UMLS CUI [1])
C0796419 (UMLS CUI [2])
C0796419 (UMLS CUI [2])
pregnancy
Item
not be pregnant
boolean
C0032961 (UMLS CUI [1])
additional inclusion criteria
Item
additional criteria to be determined at screening visit.
boolean
C1512693 (UMLS CUI [1,1])
C1524062 (UMLS CUI [1,2])
C1524062 (UMLS CUI [1,2])
previous chemotherapy regimens
Item
more than 3 previous chemotherapy regimens
boolean
C0392920 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
C0205156 (UMLS CUI [1,2])
breast cancer therapy with non cytotoxic agents
Item
more than one treatment with non cytotoxic agents for breast cancer therapy (e.g. herceptin [trastuzumab] or avastin [bevacizumab)
boolean
C0006142 (UMLS CUI [1,1])
C0087111 (UMLS CUI [1,2])
C2827065 (UMLS CUI [1,3])
C0087111 (UMLS CUI [1,2])
C2827065 (UMLS CUI [1,3])
treatment with epothilones
Item
prior treatment with epothilones (e.g. ixabepilone)
boolean
C1136012 (UMLS CUI [1])
symptomatic brain metastases
Item
symptomatic brain metastases
boolean
C0220650 (UMLS CUI [1,1])
C0231220 (UMLS CUI [1,2])
C0231220 (UMLS CUI [1,2])
additional exclusion criteria
Item
additional criteria to be determined at screening visit
boolean
C0680251 (UMLS CUI [1,1])
C1524062 (UMLS CUI [1,2])
C1524062 (UMLS CUI [1,2])